Skip to main content

Select Bio, GenNext to Co-Develop Genomic, Proteomic Seminars

NEW YORK (GenomeWeb News) — GenNext Technologies and Select Biosciences plan to co-produce meetings and educational programs that combine their experience in microarrays, proteomics, translational medicine, clinical genomics, and bioinformatics, among other disciplines, the firms said last Friday.
 
Select Bio said that by combining their knowledge the companies plan to offer professional development classes that will help researchers “enhance their careers.”
 
GenNext said the courses will blend “theory” with “how-to information.”
 
Select Bio has run meetings and courses covering topics such as molecular diagnostics, drug/target screening, microarrays, RNAi biomarkers, and proteomics.
 
GenNext, meantime, has created educational programs on translational medicine, clinical genomics, proteomics, and bioinformatics research.   

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.